# PGP-UK Genomics Report for PGP-UK1/uk35C650 

## 1 Summary

This is the genome report was produced using collaborative research tools, including SNPedia and GetEvidence. This section shows an overview of all the small variants which were found in the genome for this individual, when compared with a reference genome. These variants are summarised in Table 1 and the pie-charts in Figures 2, 3 and 4.

This report was generated automatically and is not clinically approved. It is provided for personal and research purposes only.

This document contains hyperlinks, shown in grey, that will take you to external websites where you can find more detailed explanations. Some of the technical terms are also explained in more detail in the Ensembl Glossary. We would welcome your feedback about this report, for example, if you would like more information about anything or if any of the links have become inactive. You can contact us on: pgp-uk@ucl.ac.uk.

This summary shows an overview of all the variants which were found in the genome for this individual. The "variants remaining after filtering" refers to any differences in the DNA identified when compared to the reference genome. Of these, the majority will have already been found in some other sequenced individual and put on a database (existing variants) while others have not yet been annotated (novel variants).
"Overlapped genes" refers to the number of times where a variant was found in a region of the genome containing a gene. The diagram in Figure 1 is a simplification of the usual gene structure. "Exon" refers to the part of the gene which goes on to form a protein, and variants in this part of the gene are more likely to cause changes in the shape of the protein. Upstream, downstream, intronic and intergenic variants are more likely to alter the regulation of that gene but will not change the protein itself.

A transcript for a protein-coding gene can include the exons, introns and other gene features that are transcribed and important for gene function but might not be translated into the final protein. Not all transcripts are for protein-coding genes, with many containing non-coding RNAs that can be overlapping other genes, in introns or in intergenic regions.


Figure 1: Diagram of gene structure indicating locations of potential variants

| Feature | Count |
| :--- | :--- |
| Lines of input read | 4130989 |
| Variants remaining after filtering | 4105273 |
| Novel / existing variants | $103667(2.5 \%) / 4001606(97.5 \%)$ |
| Overlapped genes | 54674 |
| Overlapped transcripts | 64349 |
| Overlapped regulatory features | 211555 |

Table 1: Variant calling summary

There are several different types of genomic variants. The most common change is when one single building block of the DNA (called a nucleotide) is changed, called a single nucleotide variants (SNV). Other variant types include insertions, where the DNA in the individual is longer than the reference sequence due to the insertion of one or more nucleotides; and deletions, where a few nucleotides are missing compared to the reference sequence.

Some of these changes will have no effect on the protein, while some changes may alter the protein function to varying degrees. The PolyPhen analysis software attempts to quantify the effect each mutation will have on the protein function. This ranges from "benign" where no change to the protein function is expected, to "probably damaging" where it is predicted that the mutation will affect protein function. It is nevertheless important to note that what is "damaging" for the protein is not necessarily damaging for the individual.


Figure 2: PolyPhen Summary


Figure 3: Variant Class


Intergenic variant
Figure 4: Consequence type

## 2 Ancestry

This plot shows the distribution of the genomes of different populations. Data from several studies which used whole genome sequencing was used to see the relationships between the genomes of the populations. It shows how closely related certain populations are genetically: Groups which cluster closely are more genetically similar than groups which are further apart. The black star symbol shows where this PGP-UK participant sits in relation to other populations, indicating their ancestry and their most closely related populations according to genetic sequence.

Please note that this analysis is limited by the populations available in the 1 kGP data. If there are European subpopulations reported, and the ancestry of the participant does not correspond to any of the 1 kGP populations, the closest 1 kGP sampled subpopulation will be shown (even though it might be different from the participant's actual ancestry).

## Ancestry PGP-UK1



Figure 5: Ancestry Principal Component Analysis

## 3 Traits (based on SNPedia information)

Existing research has associated many variants with phenotypic traits, some of which can be perceived as beneficial while others appear to have a harmful effect. Some traits are complex and can be affected by several variants. It is likely that some of these would confer a higher risk while others a lower risk of trait manifestation. These can not be combined linearly to produce an actual risk of disease.

It is important to note that in most cases genomic data is probabilistic, not deterministic- i.e. having a genetic predisposition for a disease is not a diagnosis; rather, it shows an increased likelihood of developing that disease. Also, one person can have both potentially beneficial and harmful variants in the same gene, or associated with the same disease.

Some variants can also affect certain populations more, or will only affect a particular gender. For example, a variant for higher risk of endometriosis in the sequence of a male will not directly affect that person, but can be passed on to descendants.

While many traits are the result of a unique variant, many are the combination of several variants throughout the genome. In SNPedia, these are called genosets. These can integrate some of the information already present in the single variant tables, or be the combination of variants that have no phenotypic effect on their own, but contribute to a trait when together.

The variants in the following tables are sorted by magnitude. This is an subjective measure defined in SNPedia to highlight the perceived importance of the genotype described. At the moment this scale goes from 0 to 10 . You can read more about it by visiting their explanatory webpage.

As our knowledge grows, the interpretation of the effect of certain variants might change. Clicking on the links in the genome report tables will take you to websites containing more information about each variant.

### 3.1 Possibly Beneficial Traits

| Mag. | Identifier | Genotype | Summary | GnomAD | GetEvidence | ClinVar |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 3 | rs7294919 | (C;T) | Moderately enhanced hippocampal volume | Link |  |  |
| 3 | rs8177374 | (C;T) | Resistance to several diseases | Link | Link | Link |
| 2.5 | rs2943634 | ( $\mathrm{A} ; \mathrm{A}$ ) | Lower risk of ischemic stroke | Link | Link |  |
| 2.2 | rs2511989 | ( $\mathrm{A} ; \mathrm{A}$ ) | 0.44x decreased age-related macular degeneratio... | Link | Link |  |
| 2.1 | rs547154 | ( $\mathrm{A} ; \mathrm{A}$ ) | 0.47x decreased risk for AMD | Link |  | Link |
| 2.1 | rs806380 | (G;G) | Uncommon. lowest odds of cannabis dependence | Link |  |  |
| 2 | rs1026732 | ( $\mathrm{A} ; \mathrm{A}$ ) | $<0.70 \mathrm{x}$ risk for restless legs | Link | Link |  |
| 2 | rs10503669 | ( $\mathrm{A} ; \mathrm{C}$ ) | Associated with higher HDL cholesterol | Link | Link |  |
| 2 | rs10504861 | (A;G) | Reduced risk of migraine without aura | Link |  |  |
| 2 | rs11635424 | ( $\mathrm{A} ; \mathrm{A}$ ) | $<0.70 \mathrm{x}$ risk for restless legs | Link | Link |  |
| 2 | rs12593813 | ( $\mathrm{A} ; \mathrm{A}$ ) | $<0.71$ x risk for restless legs | Link | Link |  |
| 2 | rs12678919 | (A;G) | Associated with higher HDL cholesterol | Link | Link |  |
| 2 | rs12979860 | (C;C) | $\sim 80 \%$ of such hepatitis C patients respond to tr... | Link | Link | Link |
| 2 | rs1544410 | (G;G) | Decreased risk of low bone mineral density diso... | Link | Link |  |
| 2 | rs1799884 | (G;G) | Mothers have typical Birth-Weight babies. Sligh... | Link |  |  |
| 2 | rs1800972 | (G;G) | Reduced risk for Crohn's disease; reduced risk ... | Link |  |  |
| 2 | rs1864163 | (A;G) | Associated with higher HDL cholesterol | Link | Link |  |
| 2 | rs2060793 | (A;A) | Lower serum levels of vitamin D | Link |  |  |
| 2 | rs2235015 | (G;T) | Somewhat more likely to respond to certain anti... | Link | Link |  |
| 2 | rs261332 | (A;G) | Associated with higher HDL cholesterol | Link |  |  |
| 2 | rs3738579 | (C;T) | 0.5x decreased risk for cervical cancer: HNSCC:... | Link |  |  |
| 2 | rs3764261 | (G;T) | Associated with higher HDL cholesterol | Link | Link | Link |
| 2 | rs3914132 | (C;T) | Lower otosclerosis risk | Link | Link |  |
| 2 | rs4143094 | (G;G) | No increased risk of colorectal cancer correlat... | Link |  |  |
| 2 | rs4149268 | (G;G) | Associated with higher HDL cholesterol | Link | Link |  |
| 2 | rs4585 | (G;G) | Slightly higher (1.35x) odds of good metformin ... | Link |  | Link |
| 2 | rs505922 | (T;T) | Blood type O | Link | Link |  |


| Mag. | Identifier | Genotype | Summary | GnomAD | GetEvidence | ClinVar |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 2 | rs6505162 | (A;C) | 0.58x decreased risk for esophageal cancer | Link |  |  |
| 2 | rs6511720 | (G;T) | Slightly lower odds of developing CHD. | Link | Link | Link |
| 2 | rs7776725 | (T;T) | Stronger bones | Link | Link |  |
| 2 | rs801114 | ( $\mathrm{T} ; \mathrm{T}$ ) | 0.78x decreased Basal Cell Carcinoma risk. | Link | Link |  |
| 1.8 | rs1800588 | (C;T) | Higher HDL-C levels | Link | Link |  |
| 1.8 | rs187238 | (C;G) | Hypertension not a risk factor for sudden cardi... | Link |  |  |
| 1.8 | rs4714156 | (C;C) | $<0.61$ x risk for restless legs | Link |  |  |
| 1.8 | rs6897932 | (C;T) | 0.91x decreased risk for multiple sclerosis | Link | Link | Link |
| 1.5 | rs11136000 | (C;T) | 0.84x decreased risk for Alzheimer's disease | Link | Link |  |
| 1.5 | rs11212617 | (C;C) | Somewhat increased likelihood of treatment succ... | Link |  | Link |
| 1.5 | rs309375 | (G;G) | Smaller mosquito bites | Link |  |  |
| 1.5 | rs3851179 | (A;A) | 0.85x decreased risk for Alzheimer's disease | Link | Link |  |
| 1.5 | rs4149274 | (C;C) | Associated with higher HDL (good) cholesterol. | Link |  |  |
| 1.5 | rs4939883 | (C;T) | Associated with higher HDL cholesterol | Link | Link |  |
| 1.2 | rs11172113 | (C;C) | 0.8x lower risk for migraines | Link |  |  |
| 1.2 | rs11246226 | (A;C) | Decreased risk of schizophrenia in limited stud... | Link | Link |  |
| 1.2 | rs6048 | (G;G) | Slightly lower risk (10-20\%) of deep vein throm... | Link | Link | Link |
| 1.2 | rs9306160 | (C;T) | 0.75x (reduced) risk for metastasis in LN -/ $\mathrm{ER}+\ldots$ | Link | Link |  |
| 1.1 | rs2293347 | (G;G) | Among NSCLC patients: better Gefitinib response... | Link |  | Link |
| 1 | rs10248420 | (A;G) | 7x more likely to respond to certain antidepres... | Link | Link |  |
| 1 | rs11983225 | (C;T) | 7x more likely to respond to certain antidepres... | Link | Link |  |
| 1 | rs182549 | (C;T) | Can digest milk. | Link |  | Link |
| 1 | rs2235040 | (A;G) | 7x more likely to respond to certain antidepres... | Link | Link |  |
| 1 | rs2235067 | (A;G) | 7x more likely to respond to certain antidepres... | Link |  |  |
| 1 | rs2494732 | (T; T ) | Lower odds of psychosis | Link | Link |  |
| 1 | rs25640 | ( $\mathrm{A} ; \mathrm{A}$ ) | Benign polymorphism | Link | Link | Link |
| 1 | rs2952768 | (C;T) | Slightly less drug dependence: decreased effect... | Link |  | Link |
| 1 | rs3755319 | (G;T) | Most likely a benign polymorphism | Link |  | Link |
| 1 | rs4129267 | (C;C) | No increased risk of higher IL-R and CRP levels... | Link | Link |  |
| 1 | rs4148739 | (A;G) | 7x more likely to respond to certain antidepres... | Link | Link |  |
| 1 | rs4939827 | (C;T) | 0.86 x decreased risk for colorectal cancer | Link | Link | Link |
| 1 | rs7850258 | (A;G) | Typical odds of developing primary hypothyroidi... | Link |  |  |
| 1 | rs800292 | (C;T) | 1\% decreased risk of macular degeneration | Link | Link | Link |
| 1 | rs8179183 | (C;G) | Less likely to gain weight if taking risperidon... |  | Link |  |
| 0.1 | rs1538660 | (C;T) | Likely to be a benign variant | Link | Link | Link |
| 0.1 | rs3204145 | ( $\mathrm{A} ; \mathrm{T}$ ) | Likely to be a benign variant | Link | Link | Link |

### 3.2 Possibly Harmful Traits

| Mag. | Identifier | Genotype | Summary | GnomAD | GetEvidence | ClinVar |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 3 | rs2066847 | (-; C$)$ | 3x higher risk of Crohn's disease | Link |  | Link |
| 3 | rs2981582 | (C;T) | 1.3x higher risk of $\mathrm{ER}+$ breast cancer | Link | Link |  |
| 2.7 | rs10830963 | (C;G) | Increased type-2 diabetes risk; higher gestatio... | Link | Link |  |
| 2.5 | rs10974944 | (C;G) | Increased odds (2-4 fold?) of V617F-associate... | Link | Link |  |
| 2.5 | rs12340895 | (C;G) | Increased odds (2 fold?) of developing V617F-po... | Link |  |  |
| 2.5 | rs12343867 | (C;T) | Increased odds (2 fold?) of V617F-associated MP... | Link |  |  |
| 2.5 | rs12803066 | (A;G) | Increased risk of myopia | Link |  |  |
| 2.5 | rs13266634 | (C;T) | Increased risk for type-2 diabetes | Link | Link | Link |
| 2.5 | rs1421085 | (C;T) | ${ }^{\sim} 1.3 \mathrm{x}$ increased obesity risk | Link | Link | Link |
| 2.5 | rs16969968 | (A;G) | Slightly higher risk for nicotine dependence: l... | Link | Link | Link |
| 2.5 | rs2004640 | (T;T) | 1.4x increased risk for SLE | Link | Link | Link |
| 2.5 | rs2254958 | (C;C) | 1.61x increased risk for Alzheimer's | Link |  |  |
| 2.5 | rs3738919 | (C;C) | 1.94x risk of developing rheumatoid arthritis | Link |  |  |
| 2.5 | rs3780374 | (A;G) | Substantially increased odds of developing V617... | Link |  |  |
| 2.5 | rs4495487 | (C;T) | Increased odds (2 fold?) of developing V617F-as... | Link |  |  |
| 2.5 | rs5888 | (C;T) | 3 x higher risk for age-related macular degenera... | Link |  |  |
| 2.5 | rs664143 | (T; T ) | Higher risk for number of cancers | Link |  |  |
| 2.5 | rs8034191 | ( $\mathrm{C} ; \mathrm{T}$ ) | 1.27x lung cancer risk | Link | Link |  |
| 2.3 | rs1859962 | (G;G) | 1.28 x increased risk for prostate cancer | Link | Link |  |
| 2.3 | rs7966230 | (C;G) | Slightly lower levels of plasma VWF | Link |  |  |
| 2.1 | rs10427255 | (C;C) | Highest odds of photic sneeze reflex | Link |  |  |
| 2.1 | rs10811661 | (T;T) | 1.2 x increased risk for type-2 diabetes | Link | Link |  |
| 2.1 | rs17070145 | (C;C) | Reduced memory abilities | Link |  | Link |
| 2.1 | rs17563 | (C;C) | Risk for otosclerosis | Link | Link | Link |
| 2.1 | rs2306402 | (C;C) | 1.18x increased risk for late-onset Alzheimer's... | Link |  |  |
| 2.1 | rs4430796 | (A;A) | 1.38x increased risk for prostate cancer | Link | Link |  |
| 2.1 | rs4444903 | (G;G) | 3.5x risk of hep-cancer in cirrhosis patients; ... | Link |  | Link |
| 2.1 | rs646776 | $(\mathrm{A} ; \mathrm{A})$ | 1.2 x risk of coronary artery disease | Link | Link |  |
| 2.1 | rs795484 | (A;G) | Increased morphine dose requirement and postope... | Link |  |  |
| 2.1 | rs944289 | (C;T) | 1.3x increased thyroid cancer risk | Link | Link |  |
| 2 | rs10086908 | (C;T) | 1.7 x increased risk for prostate cancer | Link |  |  |
| 2 | rs1045642 | (C;T) | Slower metaboliser for some drugs | Link | Link | Link |
| 2 | rs10488631 | (C;T) | 2x increased risk of developing SLE; 1.6x incre... | Link | Link |  |
| 2 | rs1050631 | (C;T) | Mean Survival Time of 25 months for esophageal ... | Link |  |  |
| 2 | rs1051730 | (C;T) | 1.3 x increased risk of lung cancer | Link | Link | Link |
| 2 | rs10871777 | (A;G) | Adults likely to be 0.22 BMI units higher | Link |  |  |
| 2 | rs10889677 | ( $\mathrm{A} ; \mathrm{C}$ ) | 1.5x increased risk for certain autoimmune dise... | Link | Link |  |
| 2 | rs10984447 | (A;A) | $>1.17 \mathrm{x}$ increased risk for multiple sclerosis | Link | Link |  |
| 2 | rs11045585 | (A;G) | 63\% chance (higher than average) of docetaxel-i... | Link | Link |  |
| 2 | rs11123857 | (G;G) | 2.88-fold risk of bipolar disorder or major dep... | Link |  |  |
| 2 | rs11190870 | (C;T) | Possibly increased risk of scoliosis | Link |  |  |
| 2 | rs1143699 | (C;C) | In men: 2.19x risk of type 2 diabetes | Link |  |  |
| 2 | rs11572080 | (A;A) | $>1.81 \mathrm{x}$ risk of GI bleeding with NSAID drugs | Link | Link | Link |
| 2 | rs1160312 | (A;G) | 1.6x increased risk of Male Pattern Baldness. | Link | Link |  |
| 2 | rs1219648 | (A;G) | 1.20 x risk for breast cancer | Link | Link |  |
| 2 | rs12567232 | (A;G) | Increased risk for Crohn's Disease | Link | Link |  |
| 2 | rs12696304 | (C;G) | Prone to aging faster: at least in European pop... | Link |  |  |
| 2 | rs13254738 | (A;C) | 1.18x prostate cancer risk | Link | Link |  |
| 2 | rs1333048 | ( $\mathrm{A} ; \mathrm{C}$ ) | 1.3x increased coronary artery disease risk | Link |  |  |
| 2 | rs13376333 | (T;T) | ${ }^{\sim} 2 \mathrm{x}$ higher risk of atrial fibrillation | Link | Link |  |
| 2 | rs1360780 | (C;T) | 1.3x increased risk for depression | Link | Link | Link |
| 2 | rs144848 | (G;G) | Very slightly increased breast cancer risk | Link | Link | Link |
| 2 | rs1585215 | (A;G) | 2x increased risk for Hodgkin lymphoma | Link |  |  |


| Mag. | Identifier | Genotype | Summary | GnomAD | GetEvidence | ClinVar |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 2 | rs1691053 | (A;G) | Increased risk of developing prostate cancer | Link |  |  |
| 2 | rs16942 | (A;G) | Very slightly increased breast cancer risk | Link | Link | Link |
| 2 | rs16944 | (G;G) | Slightly increased ( ${ }^{2} \mathrm{x}$ or less) risk for certa... | Link | Link |  |
| 2 | rs1734791 | (A;A) | 1.4 x increased risk for lupus | Link |  |  |
| 2 | rs17782313 | (C;T) | Adults likely to be 0.22 BMI units higher | Link | Link | Link |
| 2 | rs1799853 | (T; T) | 40\% reduction in warfarin metabolism: greater... | Link | Link | Link |
| 2 | rs2073963 | (G;T) | Increased risk of baldness | Link |  |  |
| 2 | rs2143340 | (C;T) | Increased risk of dyslexia and poor reading per... | Link |  |  |
| 2 | rs2201841 | (C;T) | 1.5x increased risk for Crohn's disease; 2x inc... | Link | Link |  |
| 2 | rs2230201 | (G;G) | $>1.4 \mathrm{x}$ risk of lupus | Link |  | Link |
| 2 | rs2274223 | (A;G) | 1.5x increased risk for stomach and esophageal ... | Link | Link | Link |
| 2 | rs2383206 | (A;G) | 1.4 x increased risk for heart disease | Link |  |  |
| 2 | rs2383207 | (A;G) | Increased risk for heart disease | Link |  |  |
| 2 | rs241448 | (C;T) | 1.51x increased risk for Alzheimer's | Link |  | Link |
| 2 | rs2420946 | (C;T) | 1.20x risk for breast cancer | Link |  |  |
| 2 | rs25487 | (G;G) | 2x higher risk for skin cancer; possibly other ... | Link | Link | Link |
| 2 | rs2707466 | (G;G) | Weaker bones | Link | Link |  |
| 2 | rs2736990 | (C;C) | Increased risk of developing Parkinson's Diseas... | Link | Link |  |
| 2 | rs27388 | (A;A) | Increased risk of developing schizophrenia | Link |  |  |
| 2 | rs2908004 | (C;C) | Weaker bones | Link | Link |  |
| 2 | rs3212227 | ( $\mathrm{A} ; \mathrm{C}$ ) | Significantly increased risk of developing cerv... | Link |  | Link |
| 2 | rs358806 | (C;C) | 1.78x increased risk of developing Type-2 diabe... | Link | Link |  |
| 2 | rs3775948 | (G;G) | Slightly higher risk for gout | Link |  |  |
| 2 | rs4027132 | (A;A) | 1.51x increased risk of developing bipolar diso... | Link |  |  |
| 2 | rs4129148 | (C;G) | 3 x risk of schizophrenia. | Link | Link |  |
| 2 | rs4633 | (T; T ) | Higher risk for endometrial cancer | Link | Link | Link |
| 2 | rs4792311 | (A;G) | Increased risk of prostate cancer | Link | Link | Link |
| 2 | rs493258 | (G;G) | 1.15x risk of Age Related Macular Degeneration | Link |  |  |
| 2 | rs4968451 | (A;C) | 1.61x increased risk for meningioma | Link |  |  |
| 2 | rs520354 | (A;A) | Increased risk in men for biliary conditions | Link |  |  |
| 2 | rs5759167 | (T;T) | Higher prostate cancer risk | Link | Link |  |
| 2 | rs6441286 | (G;T) | 1.54 x chance of developing primary biliary cirr... | Link | Link |  |
| 2 | rs6457617 | (C;T) | 2.3x risk of rheumatoid arthritis | Link | Link |  |
| 2 | rs6603272 | (G;T) | 2.74x increased risk of developing schizophreni... | Link |  |  |
| 2 | rs6896702 | ( $\mathrm{T} ; \mathrm{T}$ ) | Increased risk of developing Parkinson's Diseas... | Link |  |  |
| 2 | rs6922269 | (A;A) | 1.6x risk of coronary artery disease | Link | Link |  |
| 2 | rs6997709 | (G;T) | 1.2x higher risk for hypertension | Link |  |  |
| 2 | rs699 | (C;T) | Increased risk of hypertension | Link | Link | Link |
| 2 | rs7216389 | (T; T ) | 1.5x increased risk for Childhood Asthma. | Link | Link |  |
| 2 | rs7442295 | (A;A) | ${ }^{\sim} 4 \mathrm{x}$ higher risk for hyperuracemia | Link | Link | Link |
| 2 | rs744373 | (C;T) | 1.17x risk of Alzheimer's | Link |  |  |
| 2 | rs7536563 | (A;A) | $>1.12 \mathrm{x}$ risk of multiple sclerosis | Link | Link |  |
| 2 | rs7794745 | ( $\mathrm{A} ; \mathrm{T}$ ) | Slightly increased risk for autism | Link | Link | Link |
| 2 | rs7807268 | (C;G) | 1.3x risk for Crohn's disease | Link | Link |  |
| 2 | rs7961152 | (A;C) | 1.2 x higher risk for hypertension | Link |  |  |
| 2 | rs828907 | (G;T) | Slightly increased risk of bladder cancer and 2... | Link |  |  |
| 2 | rs9652490 | (A;A) | ${ }^{\text {2 }}$ x increased risk for Parkinson's disease: and... | Link | Link |  |
| 2 | rs965513 | (A;G) | 1.77 x increased thyroid cancer risk | Link | Link |  |
| 2.0 | rs2156921 | (G;G) | 1.29x increased risk for depression | Link |  |  |
| 2.0 | rs2305795 | (A;A) | 1.64x higher risk of narcolepsy compared to (G;... | Link |  | Link |
| 2.0 | rs9642880 | (T;T) | 1.5x increased bladder cancer risk | Link | Link |  |
| 1.8 | rs6700125 | (C;T) | 1.2x increased risk for ALS | Link |  |  |
| 1.7 | rs8055236 | (G;T) | 1.9x risk for heart disease | Link | Link |  |
| 1.6 | rs1537415 | (C;G) | 1.6x increased risk for periodontitis | Link | Link |  |
| 1.6 | rs1978237 | (C;G) | 1.59 x risk of Type 2 diabetes | Link |  |  |


| Mag. | Identifier | Genotype | Summary | GnomAD | GetEvidence | ClinVar |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1.6 | rs2046210 | (T; T ) | 1.6x increased breast cancer risk in certain wo... | Link | Link | Link |
| 1.6 | rs2736100 | (G;G) | 1.6x higher risk for glioma development | Link | Link | Link |
| 1.6 | rs356219 | (G;G) | 1.6x increased risk for Parkinson's disease | Link |  |  |
| 1.6 | rs3764880 | (A;A) | 1.2-1.8x increased tuberculosis risk | Link | Link |  |
| 1.5 | rs10492519 | (A;G) | Slightly increased risk of developing prostate ... | Link |  |  |
| 1.5 | rs10757272 | (C;T) | 1.30x increased risk for Coronary artery diseas... | Link |  |  |
| 1.5 | rs10859871 | ( $\mathrm{A} ; \mathrm{C}$ ) | Slight ( $\sim 1.2 \mathrm{x}$ ) increase in endometriosis risk | Link |  |  |
| 1.5 | rs10883365 | (A;G) | 1.2 x increased risk for developing Crohn's dise... | Link | Link |  |
| 1.5 | rs12037606 | (A;G) | 1.22x risk of developing Crohn's disease | Link |  |  |
| 1.5 | rs12210050 | (C;T) | Slightly higher risk for basal cell carcinoma | Link | Link |  |
| 1.5 | rs1223271 | (A;G) | Slightly increased risk of developing Parkinson... | Link | Link |  |
| 1.5 | rs12431733 | (C;T) | Slightly increased risk of developing Parkinson... | Link | Link |  |
| 1.5 | rs12498742 | (A;A) | 1.25 increased risk for gout | Link |  |  |
| 1.5 | rs13149290 | (C;C) | Slightly increased risk of developing prostate ... | Link |  |  |
| 1.5 | rs140701 | (A;A) | Increased risk for anxiety disorders | Link |  |  |
| 1.5 | rs17221417 | (C;G) | 1.3x higher risk for Crohn's disease | Link | Link |  |
| 1.5 | rs1801274 | (T; T) | Complex; generally greater risk for cancer prog... | Link | Link | Link |
| 1.5 | rs2177369 | (C;C) | 1.5x increased risk for Alzheimer's disease | Link |  |  |
| 1.5 | rs2240340 | (A;G) | Slightly increased (1.5x) risk for RA | Link |  |  |
| 1.5 | rs2272127 | (C;C) | Associated with herpes and schizophrenia | Link |  |  |
| 1.5 | rs2280714 | (A;A) | 1.4x increased risk of SLE | Link |  |  |
| 1.5 | rs28694718 | ( $\mathrm{A} ; \mathrm{A}$ ) | $>2 \mathrm{x}$ higher risk for schizophrenia | Link |  |  |
| 1.5 | rs3087243 | (A;G) | Increased risk for auto-immune diseases | Link | Link | Link |
| 1.5 | rs356220 | ( $\mathrm{T} ; \mathrm{T}$ ) | Increased risk of Parkinson's Disease | Link |  |  |
| 1.5 | rs3745516 | (A;G) | Slightly increased risk of developing primary b... | Link |  |  |
| 1.5 | rs3814570 | (C;T) | 1.3x increased risk for Crohn's disease with il... | Link |  |  |
| 1.5 | rs3825776 | (A;G) | 1.3x increased risk for ALS | Link | Link |  |
| 1.5 | rs393152 | (A;A) | Increased risk of both PD and AD | Link | Link |  |
| 1.5 | rs401681 | (C;T) | ~1.2x increased risk for several types of cance... | Link | Link |  |
| 1.5 | rs4464148 | (C;T) | 1.10x increased risk for colorectal cancer | Link |  |  |
| 1.5 | rs4538475 | (A;G) | Slightly increased risk of developing Parkinson... | Link | Link |  |
| 1.5 | rs4626664 | (A;G) | 1.44x increased risk of developing restless leg... | Link | Link |  |
| 1.5 | rs464049 | (T; T ) | Increased risk of schizophrenia in limited stud... | Link |  |  |
| 1.5 | rs486907 | (A;G) | 1.5x increased prostate cancer risk | Link | Link | Link |
| 1.5 | rs4982731 | (C;C) | Possible higher risk of childhood acute lymphob... | Link |  |  |
| 1.5 | rs5219 | (C;T) | 1.3x increased risk for type-2 diabetes | Link | Link | Link |
| 1.5 | rs5746059 | (A;A) | Slightly higher fat mass | Link |  |  |
| 1.5 | rs6435862 | (G;T) | 1.7x higher risk of aggressive neuroblastoma | Link | Link |  |
| 1.5 | rs6498169 | (A;G) | 1.14 x risk of multiple sclerosis | Link | Link |  |
| 1.5 | rs6601764 | (C;T) | 1.16x increased risk of developing Crohn's dise... | Link | Link |  |
| 1.5 | rs6656401 | (A;G) | 1.18x increased risk for late-onset Alzheimer... | Link |  |  |
| 1.5 | rs6908425 | (C;T) | 1.63x increased risk of developing Crohn's dise... | Link | Link |  |
| 1.5 | rs699473 | (C;T) | $\sim 1.5 \mathrm{x}$ increased brain tumor risk | Link |  |  |
| 1.5 | rs7774434 | (C;T) | Slightly increased risk of developing primary b... | Link |  |  |
| 1.5 | rs9561778 | (G;T) | ~2x increased risk of adverse drug reactions fr... | Link | Link |  |
| 1.5 | rs966221 | (C;C) | 1.5 x increased stroke risk certain populations | Link |  |  |
| 1.5 | rs995030 | (G;G) | Non-protective against testicular cancer | Link | Link |  |
| 1.4 | rs10134944 | (C;T) | 1.4 x risk of bipolar disorder. | Link | Link |  |
| 1.4 | rs3131296 | (G;G) | 1.4 x increased risk for schizophrenia | Link | Link |  |
| 1.4 | rs4795067 | (G;G) | Slight increase in risk for psoriatic arthritis... | Link |  |  |
| 1.4 | rs6010620 | (G;G) | 1.4 x higher risk for glioma development; but th... | Link | Link |  |
| 1.3 | rs1042713 | (A;G) | 1.3x increased risk that pediatric inhaler use ... | Link | Link | Link |
| 1.3 | rs10947262 | (C;C) | 1.3 x increased risk for osteoarthritis | Link |  |  |
| 1.3 | rs110419 | (A;G) | 1.3x increased risk for neuroblastoma | Link |  |  |
| 1.3 | rs1260326 | (C;T) | Slightly higher risk for gout | Link | Link | Link |


| Mag. | Identifier | Genotype | Summary | GnomAD | GetEvidence | ClinVar |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1.3 | rs13361189 | (C;T) | 1.3x increased risk for Crohn's disease | Link | Link |  |
| 1.3 | rs1375144 | (C;T) | 1.32x increased risk of developing bipolar diso... | Link |  |  |
| 1.3 | rs1434536 | (A;G) | 1.29x increased breast cancer risk | Link |  | Link |
| 1.3 | rs1746048 | (C;C) | 1.03 increased risk for coronary heart disease | Link | Link |  |
| 1.3 | rs2024513 | (A;G) | 1.3x higher risk for schizophrenia (among Han C... | Link |  |  |
| 1.3 | rs34330 | (C;T) | 1.3x higher risk for endometrial cancer (in Chi... | Link |  | Link |
| 1.3 | rs4712653 | (C;T) | Very slightly ( $\sim 1.3 \mathrm{x}$ ) increased risk for neurob... | Link |  |  |
| 1.3 | rs4958847 | (A;G) | 1.3x increased risk for Crohn's disease | Link |  |  |
| 1.25 | rs13387042 | (A;A) | 1.24 x increased risk for breast cancer | Link | Link |  |
| 1.2 | rs10865331 | (A;G) | 1.2 x higher risk for ankylosing spondylitis | Link |  |  |
| 1.2 | rs1344706 | (T;T) | 1.2x increased risk for schizophrenia | Link | Link |  |
| 1.2 | rs143383 | (C;T) | 1.1x increased risk for osteoarthritis | Link | Link | Link |
| 1.2 | rs1800693 | (A;G) | Slight (1.2x) increase in risk for multiple scl... | Link | Link | Link |
| 1.2 | rs2056116 | (A;G) | 1.18x risk for breast cancer | Link |  |  |
| 1.2 | rs2072590 | (G;T) | 1.2x increased risk for ovarian cancer | Link |  |  |
| 1.2 | rs2076295 | (G;T) | One copy of the risk allele (G): slightly incre... | Link |  |  |
| 1.2 | rs2252586 | (A;G) | 1.2x higher risk for glioma development | Link |  |  |
| 1.2 | rs6897876 | (C;C) | Slight increase in testicular cancer risk for m... | Link |  |  |
| 1.2 | rs7514229 | (G;G) | Associated with early-onset autoimmune thyroid ... | Link |  |  |
| 1.2 | rs8050136 | (A;C) | 1.2x increased risk for T2D in some populations... | Link | Link |  |
| 1.2 | rs851715 | (A;A) | Risk of nonsense-word repetition problems if sp... | Link |  |  |
| 1.17 | rs17465637 | (A;C) | 1.17x higher risk for myocardial infarction | Link | Link |  |
| 1.15 | rs748404 | (C;T) | Very slightly increased risk (1.15) for lung ca... | Link | Link |  |
| 1.1 | rs11037909 | (C;T) | 1.27 x type II diabetes risk | Link |  |  |
| 1.1 | rs1799966 | (A;G) | Very slightly increased breast cancer risk | Link | Link | Link |
| 1.1 | rs249954 | (C;T) | Potentially increased risk of Breast Cancer | Link |  | Link |
| 1.1 | rs2651899 | (A;G) | 1.1x higher risk for migraines | Link |  |  |
| 1.1 | rs2653349 | (G;G) | 2-6x increased risk for cluster headaches | Link | Link |  |
| 1.1 | rs34516635 | (G;G) | Less longevity for Ashkenazi Jewish women. | Link |  | Link |
| 1.1 | rs3740878 | (A;G) | 1.26x type II diabetes risk | Link |  | Link |
| 1.1 | rs3818361 | (C;T) | 1.15x increased risk for late-onset Alzheimer's... | Link |  |  |
| 1.1 | rs4977574 | (A;G) | Some studies - but not others - report a slight... | Link | Link |  |
| 1.1 | rs5030737 | (C;T) | Carrier of mannose binding deficiency but of lo... | Link | Link | Link |
| 1.1 | rs7412 | (C;T) | More likely to gain weight if taking olanzapine... | Link | Link | Link |
| 1.1 | rs7531806 | (A;G) | Very slightly increased risk of acne occurrence... | Link |  |  |
| 1.1 | rs925391 | (C;C) | More likely to go bald; common | Link |  |  |
| 1.05 | rs2291834 | (C;T) | Very slightly higher risk for myocardial infarc... | Link |  |  |
| 1 | rs1004819 | (C;T) | 1.5x risk of Crohn's disease: 1.2 for developin... | Link | Link |  |
| 1 | rs10761659 | (A;G) | 1.2x risk of Crohn's disease | Link | Link |  |
| 1 | rs1417066 | (C;T) | Slightly increased risk of osteoarthritis | Link |  |  |
| 1 | rs17300539 | (G;G) | Increased risk of insulin resistance | Link |  |  |
| 1 | rs2273697 | (A;G) | Adverse reaction more likely to carbamazepine i... | Link | Link | Link |
| 1 | rs2282679 | (A;C) | Somewhat lower vitamin D levels | Link |  |  |
| 1 | rs2546890 | (A;G) | Higher risk of multiple sclerosis | Link |  |  |
| 1 | rs3194051 | ( $\mathrm{A} ; \mathrm{A}$ ) | $>1.1 \mathrm{x}$ risk of type-1 diabetes | Link | Link | Link |
| 1 | rs5326 | (A;G) | Possible psychiatric risks | Link |  |  |
| 1 | rs6932590 | (T;T) | 1.1x increased risk for schizophrenia | Link | Link |  |
| 1 | rs6974491 | (A;G) | Higher risk of coeliac and/or inflammatory bowe... | Link |  |  |
| 1 | rs6976 | (C;T) | Slight risk of osteoarthritis | Link |  |  |
| 1 | rs7453920 | (G;G) | Slight increase in risk for chronic hepatitis B... | Link |  |  |
| 1 | rs987525 | (A;C) | 2.5x increased risk for cleft lip | Link | Link |  |
| 0.1 | rs11110912 | (C;G) | Maybe some quite minor increase in high blood p... | Link |  |  |
| 0.1 | rs3095870 | (G;G) | 1.7x increased risk for SLE (lupus) | Link |  |  |
| 0.1 | rs601338 | (A;G) | Susceptible to Norovirus infections | Link | Link | Link |

### 3.3 Genosets (Multi-variant Phenotypes)

| Magnitude | Identifier | Summary |
| :--- | :--- | :--- |
| 4 | gs144 | Male |
| 3.5 | gs126 | Poor warfarin metabolizer |
| 3.3 | gs162 | CYP2C9 Poor Metabolizers |
| 3.1 | gs122 | 7x risk of male baldness |
| 3.1 | gs191 | Impaired NSAID drug metabolism |
| 3 | gs241 | Lighter green: brown or hazel eye color |
| 3 | gs273 | Lowest risk (13\% of white women) of Atrial Fibr... |
| 2.5 | gs155 | CYP3A5 non-expressor |
| 2.5 | gs157 | More stimulated by coffee |
| 2.5 | gs259 | Homozygous for eye color haplotype \#3 |
| 2.5 | gs281 | Part of the 88\% of the population claimed not t... |
| 2.5 | gs285 | Claimed to lose 2.5x as much weight on a low fa... |
| 2.3 | gs255 | Homozygous eye color haplotype \#1 |
| 2.1 | gs223 | One copy of GCH1 variant associated with lower ... |
| 2 | gs101 | Probably able to digest milk |
| 2 | gs140 | NAT2 slow metabolizer |
| 2 | gs154 | NAT2 Slow metabolizer |
| 2 | gs173 | CYP2D6*10 |
| 2 | gs221 | Autoimmune disorder risk in Europeans |
| 2 | gs269 | APOE E2/E3 |
| 2 | gs279 | Mild trimethylaminuria |
| 1.7 | gs233 | Normal pain sensitivity; APS/APS: LPS/APS: and ... |
| 1.5 | gs185 | The beta blocker metoprolol is effective: with ... |
| 1.5 | gs220 | HLA-B*1502? |
| 1.5 | gs247 | Parkinson's Disease Risk |
| 1.2 | gs184 | Able to taste bitterness. |
| 1 | gs182 | CYP2D6*39 |

## 4 Raw Data

The raw data used to create this report has been assigned the identifier PRJEB17529 in the European Nucleotide Archive (ENA) hosted at the European Bioinformatics Institute (EBI).

These data will not be accessible unless the report is approved. This will happen by default one month after the report is issued, or if the report is approved for immediate release within the one month period. Participants can also withdraw from the study at any time in which case the report and the data will not be released and will be deleted.

If the data has already been released, it can be accessed at: http://www.ebi.ac.uk/ena/data/view/PRJEB17529

## 5 Report Metadata

| Resource | Version | Website |
| :--- | :--- | :--- |
| Genome | GRCh37 | Link |
| BWA | 0.7 .12 | Link |
| SAMtools | 1.3 | Link |
| GATK | $3.4-46$ | Link |
| PLINK | v1.90b3.35 | Link |
| SNPedia | 02-Aug-2018 | Link |
| GnomAD | v2.0.2 | Link |
| GetEvidence | 10-Aug-2018 | Link |
| ClinVar | 10-Aug-2018 | Link |

Table 5: Analysis Pipeline Versions

Report generated on September 11, 2018.

